Ixabepilone: A novel microtubule-stabilizing agent for the treatment of metastatic breast cancer

American Journal of Health-System Pharmacy

Volumn 65, Issue 21, 2008, Pages 2017-2026

  Goodin, Susan ^a,b  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b Cancer Center of New Jersey   (United States)

Author keywords

Antineoplastic agents; Breast neoplasms; Capecitabine; Combined therapy; Dosage; Ixabepilone; Mechanism of action; Neoplasm metastasis; Resistance; Toxicity

Indexed keywords

AMPRENAVIR; ANTHRACYCLINE DERIVATIVE; ATAZANAVIR; BEVACIZUMAB; CAPECITABINE; CLARITHROMYCIN; DELAVIRDINE; DOCETAXEL; EPOTHILONE B; ERYTHROMYCIN; FLUCONAZOLE; INDINAVIR; ITRACONAZOLE; IXABEPILONE; KETOCONAZOLE; LAPATINIB; NEFAZODONE; NELFINAVIR; PACLITAXEL; PYRIMIDINE DERIVATIVE; RITONAVIR; SAQUINAVIR; TAXANE DERIVATIVE; TELITHROMYCIN; TRASTUZUMAB; VERAPAMIL; VORICONAZOLE;

ABDOMINAL PAIN; ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ASTHENIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HAND FOOT SYNDROME; HEADACHE; HUMAN; INFECTION; LEUKOPENIA; METASTASIS; MONOTHERAPY; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; MYALGIA; NAIL DISEASE; NAUSEA; NEUROPATHIC PAIN; NEUROPATHY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; REVIEW; SENSORY NEUROPATHY; STOMATITIS; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 56049127901     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070628     Document Type: Review

References (46)

1. Gennari A, Conte P, Rosso R et al. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer. 2005; 104:1742-50.
2. Hamilton A, Hortobagyi G. Chemotherapy: what progress in the last 5 years? J Clin Oncol. 2005; 23:1760-75. [Erratum. J Clin Oncol. 2006; 23:5851.]
3. Colozza M, De Azambuja E, Personeni N et al. Achievements in systemic therapies in the pregenomic era in metastatic breast cancer. Oncologist. 2007; 12:253-70.
4. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol. 2005; 205:275-92.
5. Lee JJ, Swain SM. Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR). Semin Oncol. 2005; 32(suppl 7):S22-6.
6. Clarke R, Leonessa F, Trock B. Multidrug resistance/P-glycoprotein and breast cancer: review and meta-analysis. Semin Oncol. 2005; 32(suppl 7):S9-15.
7. Fornier MN. Epothilones in breast cancer: review of clinical experience. Ann Oncol. 2007; 18(suppl 5):v16-21.
8. Goodin S, Kane M, Rubin EH. Epothilones: mechanism of action and biological activity. J Clin Oncol. 2004; 22:2015-25.
9. Aghajanian C, Burris HA, Jones S et al. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol. 2007; 25:1082-8.
10. Dawson NA. Epothilones in prostate cancer: review of clinical experience. Ann Oncol. 2007; 18(suppl 5):v22-7.
11. Larkin JM, Kaye SB. Potential clinical application of epothilones: a review of phase II studies. Ann Oncol. 2007; 18(suppl 5):v28-34.
12. Fumoleau P, Coudert B, Isambert N et al. Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol. 2007; 18(suppl 5):v9-15.
13. Altmann KH, Pfeiffer B, Arseniyadis S et al. The chemistry and biology of epothilones - the wheel keeps turning. ChemMedChem. 2007; 2:396-423.
14. Cortes J, Baselga J. Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist. 2007; 12:271-80.
15. Perez EA, Lerzo G, Pivot X et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007; 25:3407-14.
16. Roché H, Yelle L, Cognetti F et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol. 2007; 25:3415-20.
17. Denduluri N, Low JA, Lee JJ et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol. 2007; 25:3421-7.
18. Thomas E, Tabernero J, Fornier M et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol. 2007; 25:3399-406.
19. Thomas E, Gomez HL, Li RK et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007; 25:5210-7.
20. Low JA, Wedam SB, Lee JJ et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol. 2005; 23:2726-34.
21. Rowinsky EK, Calvo E. Novel agents that target tubulin and related elements. Semin Oncol. 2006; 33:421-35.
22. Lee FY, Borzilleri R, Fairchild CR et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res. 2001; 7:1429-37.
23. Nettles JH, Li H, Cornett B et al. The binding mode of epothilone A on alpha, beta-tubulin by electron crystallography. Science. 2004; 305:866-9.
24. Brooks TA, Minderman H, O'Loughlin KL et al. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol Cancer Ther. 2003; 2:1195-205. [Erratum. Mol Cancer Ther. 2004; 3:101.]
25. McDaid HM, Mani S, Shen HJ et al. Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study. Clin Cancer Res. 2002; 8:2035-43.
26. Ixabepilone package insert. Princeton, NJ: Bristol-Myers Squibb; 2007 Oct.
27. Takimoto CH, Liu PY, Lenz H et al. A phase I pharmacokinetic study of the epothilone B analogue, ixabepilone (BMS-247550) in patients with advanced malignancies and varying degrees of hepatic impairment. A SWOG early therapeutics committee and NCI organ dysfunction working group trial. J Clin Oncol. 2006; 24(suppl 18S). Abstract.
28. Blum JL, Jones SE, Buzdar AU et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999; 17:485-93.
29. Blum JL, Dieras V, Lo Russo PM et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer. 2001; 92:1759-68.
30. Reichardt P, Von Minckwitz G, Thuss-Patience PC et al. Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol. 2003; 14:1227-33.
31. Fumoleau P, Largillier R, Clippe C et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer. 2004; 40:536-42.
32. Lee FY, Camuso A, Castenada S et al. Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts. 2006 ASCO annual meeting proceedings part I. J Clin Oncol. 2006; 24(suppl):12017.
33. Bunnell CA, Klimovsky J, Thomas E. Final efficacy results of a phase I/II trial of ixabepilone in combination with capecitabine in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline. 2006 ASCO annual meeting proceedings part I. J Clin Oncol. 2006; 24(suppl):10511.
34. Vahdat LT, Klimovsky J, Bunnell C. Phase I/II trial in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline: final safety data. 2006 ASCO annual meeting proceedings part I. J Clin Oncol. 2006; 24(suppl):10528.
35. ClinicalTrials.gov. Epothilone (ixabepilone) plus capecitabine versus capecitabine alone in patients with advanced breast cancer. www.clinicaltrials. gov/ct2/show/NCT00082433?term=nct00082433&rank=1 (accessed 2008 Aug 5).
36. Jassem J, Thomas E, Gomez H et al. Phase III study of ixabepilone plus capecitabine in patients with metastatic breast cancer (MBC) progressing after anthracyclines and taxanes: subgroup analysis of patients receiving ixabepilone in the first-line setting. Eur J Cancer. 2007; 5:213. Abstract.
37. ClinicalTrials.gov. A Phase II combination of trastuzumab and ixabepilone versus trastuzumab and docetaxel in patients with advanced and/or metastatic breast cancer. www.clinicaltrials.gov/ct2/show/NCT00490646?term= NCT00490646&rank=1 (accessed 2008 Aug 4).
38. ClinicalTrials.gov. Phase I study of ixabepilone + lapatinib +/- capecitabine to treat HER2 positive locally advanced or metastatic breast cancer. www.clinicaltrials.gov/ct2/show/NCT00634088?term= phase+1+trial+of+ixabepilone+her2&rank=1 (accessed 2008 Aug 4).
39. ClinicalTrials.gov. A trial of 2 schedules of ixabepilone plus bevacizumab and paclitaxel plus bevacizumab for breast cancer. www.clinicaltrials.gov/ct2/show/NCT00370552?term=NCT00370552&rank=1 (accessed 2008 Aug 4).
40. Gianni L. Ixabepilone and the narrow path to developing new cytotoxic drugs. J Clin Oncol. 2007; 25:3389-91.
41. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule- stabilizing agents. J Clin Oncol. 2006; 24:1633-42.
42. Markman M. Management of toxicities associated with the administration of taxanes. Expert Opin Drug Saf. 2003; 2:141-6.
43. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist. 2007; 12:601-9.
44. Marse H, Van Cutsem E, Grothey A et al. Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda). Eur J Oncol Nurs. 2004; 1(suppl 8):S16-30.
45. Lee H, Xu L, Wu S et al. Predictive biomarker discovery and validation for the targeted chemotherapeutic ixabepilone. 2006 ASCO annual meeting proceedings part I. J Clin Oncol. 2006; 24(suppl):3011.
46. Rowinsky EK, Eisenhauer EA, Chaudhry V et al. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol. 1993; 20(4, suppl 3):1-15.